B Acute Lymphoblastic Leukemia Clinical Trials

42 clinical trials for B Acute Lymphoblastic Leukemia across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia — RECRUITING · PHASE2
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) — RECRUITING · PHASE2
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia — RECRUITING · PHASE3
• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy — RECRUITING · PHASE3
• Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia — RECRUITING · PHASE2
• Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia — RECRUITING · NA
• In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies — RECRUITING · PHASE1
• JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia — RECRUITING · NA
• JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia — RECRUITING · NA
• Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia — RECRUITING · PHASE2
• Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence — RECRUITING · PHASE1
• Pre-emptive Anakinra for Cytokine Event Reduction — WITHDRAWN · PHASE1
• Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease — ACTIVE_NOT_RECRUITING · PHASE2
• Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia — TERMINATED · PHASE2
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE3
• Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment — NOT_YET_RECRUITING · PHASE2
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations — COMPLETED · PHASE3
• Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE3
• CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission — ACTIVE_NOT_RECRUITING · PHASE1
• Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors — NOT_YET_RECRUITING · PHASE1
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation — TERMINATED · PHASE2
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease — COMPLETED · PHASE2
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia — COMPLETED · PHASE2
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement — COMPLETED · PHASE2
• Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL — COMPLETED · PHASE2
• CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). — OTHER · PHASE2
• TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) — COMPLETED · PHASE1
• Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia — TERMINATED · PHASE4
• Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia — OTHER
• CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) — COMPLETED · PHASE1
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia — TERMINATED · PHASE2
• The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies — OTHER · PHASE1
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma — WITHDRAWN · PHASE2
• A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia — OTHER · PHASE1

Refine this search